SCHEMBL10244300

SCHEMBL10244300

CCN(CCNC(=O)OC)C(C)c1ccc(OCc2ccccc2)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.48
MTNR1B P49286 2/20 0.48
APP P05067 3/20 0.48
HPGD P15428 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.47
F2 P00734 2/20 0.46
F10 P00742 2/20 0.46
PRSS1 P07477 2/20 0.46
F7 P08709 2/20 0.46
PRSS2 P07478 1/20 0.46
F3 P13726 1/20 0.46
PRSS3 P35030 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HTT P42858 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243525 0.85 ALOX5 (0.54) NPC1RAB9ASMN1; SMN2
SCHEMBL10244298 0.83 TDP1 (0.42) MTNR1AMTNR1BNPC1RAB9ASMN1; SMN2
SCHEMBL334955 0.82 TRPM8 (0.52) APPHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL10243497 0.79 SLC22A1 (0.43) MTNR1AMTNR1BHPGDSMN1; SMN2ALDH1A1
SCHEMBL10243935 0.79 PKM (0.45) APPALDH1A1ACHEPKM
SCHEMBL10282516 0.79 S1PR1 (0.37) ALDH1A1ACHEPKM
SCHEMBL10243697 0.78 ALDH1A1 (0.43) MTNR1AMTNR1BALDH1A1
SCHEMBL10243869 0.78 BCHE (0.37) ALDH1A1ACHE
SCHEMBL10243821 0.77 OPRK1 (0.46) MTNR1AMTNR1BRAB9AGAAACHE
SCHEMBL10243117 0.76 L3MBTL1 (0.41) MTNR1AMTNR1BHPGDALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 MTNR1A 2892/4885MTNR1B 2314/4885APP 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.